Point State Capital LP Fibrogen Inc Transaction History

Point State Capital LP

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2018 Nov 14, 2018	SELL	$56.3 - $67.25 $45.6 Million - $54.5 Million	-810,200 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$44.9 - $64.95 $17.4 Million - $25.2 Million	388,300 Added 92.04%	810,200 $50.7 Million
Q1 2018 May 15, 2018	BUY	$45.35 - $61.65 $19.1 Million - $26 Million	421,900 New	421,900 $19.5 Million

37.4M

351K

105K

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $54.4M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

Get notified when there are updates to the investment portfolio of Point State Capital LP, based on Form 13F filings with the SEC.

Stay updated on Point State Capital LP with notifications on news.